3-(4-Chlorophenyl)Glutaramic Acid

We are 3-(4-Chlorophenyl)Glutaramic Acid CAS:1141-23-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3-(4-Chlorophenyl)Glutaramic Acid
CAS.NO:1141-23-7
Synonyms:3-(4-Chlorophenyl)Glutaramic Acid
5-Amino-3-(4-chlorophenyl)-5-oxopentanoicacid
Β-(4-Chlorophenyl)Glutarimide
B-(4-CHLOROPHENYL) GLUTARIC ACID MONOAMIDE
3-(4-CHLOROPHENYL)-GLUTARIC ACID MONOAMIDE
 
Physical and Chemical Properties:
Density 1.343 g/cm3
Boiling Point 494.9ºC at 760 mmHg
Melting Point 168-170°C
Molecular Formula C11H12ClNO3
Molecular Weight 241.67100
Vapour Pressure 1.3E-10mmHg at 25°C
Index of Refraction 1.578
 
Specification:
Appearance:White crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Baclofen(CAS:1134-47-0).

3-(4-Chlorophenyl)Glutaramic Acid


Related News: As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy.2-Piperidone CAS:675-20-7 Commonly used generic drugs: the products whose patents have expired and the generic drugs of many companies have participated in the competition, and the market demand is large.10-yodo-1-decanol CAS:57395-49-0 According to the business type, it can be divided into non-CMO business of APIs and intermediates and CMO business of APIs and intermediates.4-chloro-1-benzothiophene CAS:66490-33-3 ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.

Related Products
Product Name
1-(2-Iodoethyl)-4-octylbenzene View Details
TRANS-2-HEXENAL View Details
2,3-Diaminotoluene View Details
Diosgenin manufacturer 2-Chloro-4-nitrotoluene manufacturer Sodium Nitrate manufacturer 5-(Methoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid manufacturer 1-[2-amino-6-[(2,2,2-trifluoroacetyl)amino]hexanoyl]pyrrolidine-2-carboxylic acid manufacturer